Vilnius-based biotech Caszyme opens a state-of-the-art 14,000-square-foot R&D facility to meet a growing regional demand for end-to-end CRISPR gene-editing solutions. Established in 2017, Caszyme has collaborated with multiple life science organizations aiming to enter the CRISPR field or expand their gene-editing capabilities.

The Norwegian Cancer Society partners with Cancer Research UK on a multi-project strategic partnership to maximize both countries’ drug development capabilities to benefit cancer patients. Both partners will identify potential projects from academia and biotechs for collaboration and progression to first-in-human studies and through to later-stage development, including clinical trials.

总部位于维尔纽斯的生物技术公司 Caszyme 开设了占地 14,000 平方英尺的最先进研发设施，以满足该地区对端到端 CRISPR 基因编辑解决方案不断增长的需求。 Caszyme 成立于 2017 年，已与多个生命科学组织合作，旨在进入 CRISPR 领域或扩展其基因编辑能力。

挪威癌症协会与英国癌症研究中心建立多项目战略合作伙伴关系，以最大限度地提高两国的药物开发能力，造福癌症患者。双方将确定学术界和生物技术领域的潜在项目，进行合作并推进到首次人体研究，直至后期开发，包括临床试验。